Facebook
X
LinkedIn
Forward
Re-Irradiation in Gastrointestinal Malignancies: Finding the Goldilocks Zone of “Just Right” Personalized Treatment
With increasing systemic therapy options for gastrointestinal cancer patients, re-irradiation in gastrointestinal cancers is an increasingly important treatment strategy. Gastrointestinal cancers are often aggressive and associated with high recurrence rates, including locoregional recurrences where effective treatment options may be limited. Re-irradiation offers the possibility of improved tumor control, alleviating pain or obstruction, and may potentially improve survival. It is critical for oncologists to learn about the appropriate use of re-irradiation in this challenging patient population. This activity gives a clinical overview of commonly encountered clinical scenarios in gastrointestinal cancer patients where re-irradiation may help improve patient outcomes.
Topics:
- Navigating the Challenges: Re-irradiation Strategies for Esophageal and GEJ Cancers
Alexandra Elena Hotca-Cho, MD - Re-irradiation: Locoregionally Recurrent Rectal Cancer
Krishan R. Jethwa, MD, MPH - Liver Reirradiation - The Reward for a Job Well Done
Michael Buckstein, MD, MPH - Q and A
Kevin L. Du, MD, PhD, MS - Moderator
Full Panel
This activity is available from July 14, 2026, through 11:59 p.m. Eastern time on July 13, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, radiation therapists, radiation dosimetrists, radiation biologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss appropriate recommendations for re-irradiation for locally recurrent/progressing esophageal cancers.
- Discuss appropriate recommendations for re-irradiation for locally recurrent/progressing rectal cancers.
- Discuss appropriate use of re-irradiation for recurrent/multiple liver tumors.
Moderator:
- Kevin L. Du, MD, PhD, MS, is employed by Yale School of Medicine. Dr. Du has no relevant financial relationship with ineligible companies to disclose.
Speakers:
- Alexandra Elena Hotca-Cho, MD, is employed by University of California San Francisco. Dr. Hotca-Cho has no relevant financial relationship with ineligible companies to disclose.
- Krishan R. Jethwa, MD, MPH, is employed by Mayo Clinic Rochester. Dr. Jethwa has no relevant financial relationship with ineligible companies to disclose.
- Michael Buckstein, MD, PhD, is employed by Icahn School of Medicine at Mount Sinai. Dr. Buckstein has no relevant financial relationship with ineligible companies to disclose.
Planners:
- Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until July 13, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.